Software development for drug design
We offer innovative software solutions for structure-based drug design. Discover how our technology can accelerate and improve the drug development process.
Specific issues resolved
Foldyne Research International is dedicated to creating and advancing precision compounds for the treatment of diseases with unmet medical needs across multiple drug classes. Our innovative approach to drug development has resulted in patentable intellectual property for compounds ready to advance to preclinical testing.
What makes our software competitive?
Our simulation method performs best in the area of lead optimization of small molecules on druggable protein targets. We have multiple examples of compound designs in the picomolar activity range.
Success Story: Targeting the WNT5a/ROR2 Signaling Pathway
We have been able to target the WNT5a/ROR2 signaling pathway, which is involved in multiple cancer types. We modified an existing compound into a picomolar inhibitor of Maternal Leucine Zipper Kinase (MELK). MELK as a target has been validated in Intrinsic Diffuse Pontine Glioma (DIPG) cell lines and xenograft mouse models, and is also highly overexpressed in other types of cancerous brain tissue. The target is predominantly active during embryonic development, non-toxic, and the inhibitor could become a "magic bullet" in the treatment of DIPG
Great business match for longevity and pharma startups
Our software and services are best suited for longevity and pharma startups that can benefit most from integrating our product into their workflow. Contact us today to discover how we can add value!